Prnewswire·2026-01-06 14:00Core Insights - Amgen has acquired Dark Blue Therapeutics Ltd., a UK-based biotechnology company, for a transaction valued at up to $840 million, enhancing its oncology portfolio with a novel investigational small molecule aimed at treating acute myeloid leukemia (AML) [1][2]. Company Overview - Amgen is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative medicines for various diseases, including cancer, heart disease, and rare diseases, leveraging over 40 years of industry experience [4]. - The company has been recognized as one of the "World's Most Innovative Companies" and "America's Best Large Employers," and is part of the Dow Jones Industrial Average and Nasdaq-100 Index [5]. Acquisition Details - The acquisition introduces a small molecule that targets and degrades two proteins (MLLT1/3) associated with specific types of AML, showing promising anti-cancer activity in preclinical models [2]. - Amgen plans to integrate Dark Blue Therapeutics into its existing research organization, which will bolster its early oncology discovery efforts and align with its strategy to invest in novel therapeutic targets [3].